Cargando…
Regeneration of Pancreatic β-Cells for Diabetes Therapeutics by Natural DYRK1A Inhibitors
The pathogenesis of diabetes mellitus is characterized by insulin resistance and islet β-cell dysfunction. Up to now, the focus of diabetes treatment has been to control blood glucose to prevent diabetic complications. There is an urgent need to develop a therapeutic approach to restore the mass and...
Autores principales: | Guo, Yichuan, Li, Lingqiao, Yao, Yuanfa, Li, Hanbing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865674/ https://www.ncbi.nlm.nih.gov/pubmed/36676976 http://dx.doi.org/10.3390/metabo13010051 |
Ejemplares similares
-
A natural DYRK1A inhibitor as a potential stimulator for β‐cell proliferation in diabetes
por: Zheng, Mengzhu, et al.
Publicado: (2021) -
The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer
por: Friedman, Eileen
Publicado: (2010) -
Natural Aristolactams and Aporphine Alkaloids as Inhibitors of CDK1/Cyclin B and DYRK1A
por: Marti, Guillaume, et al.
Publicado: (2013) -
DYRK1A Kinase Inhibitors Promote β-Cell Survival and Insulin Homeostasis
por: Barzowska, Agata, et al.
Publicado: (2021) -
DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance
por: Gruber, Wolfgang, et al.
Publicado: (2016)